MicroRNA-466a-3p attenuates allergic nasal inflammation in mice by targeting GATA3. (30th June 2019)

• Record Type: Journal Article
• Authors: Chen, Z; Deng, Y; Li, F; Xiao, B; Zhou, X; Tao, Z
• Is Part Of: Clinical and experimental immunology. Volume 197:Number 3(2019)
• Page Start: 366
• Page End: 375
• Publication Date: 2019-06-30
• Subjects: allergic rhinitis -- GATA-3 -- microRNA -- miR-466a-3p -- Th2 cell; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.13312
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Allergic rhinitis is thought to be an allergic disease associated with immunoglobulin (Ig)E-mediated immune response, characterized by increased T helper type 2 (Th2) cytokine production, elevated eosinophil levels in the nasal mucosa and induced nasal secretions. MicroRNA (miRNA) microarray data revealed that the expression level of miR-466a-3p was significantly decreased. Notably, GATA binding protein (GATA-3) was identified as one of its target genes through miRNA target prediction web tools. The expression levels of miR-466a-3p were altered by mimics and lentivirus both in vivo and in vitro, similar to those of GATA-3. Furthermore, the symptoms and histology of allergic rhinitis as well as the levels of serum IgE and interleukin (IL)-4 were examined in different groups of mice. Interestingly, the results for lentiviral miR-466a-3p-treated allergic rhinitis mice were relatively similar to normal mice, compared to allergic rhinitis mice without treatment. Also, miR-466a-3p negatively regulated GATA-3 expression in allergic rhinitis mice, indicating the participant of Th2-cell responses in allergic rhinitis. Taken together, our findings highlight a new perspective on the role of miR-466a-3p in allergic rhinitis. In addition, this study provides a theoretical framework and experimental reference for future research targeting microRNAs as therapeutic targets and diagnostic biomarkers of allergic rhinitis. Graphical Abstract: